Aflac 1, Major Medical 0
If a duck quacks in the forest and no investor is around to hear it, does it make a noise? The answer appears to be a resounding yes!
In its ongoing battle against major medical, supplemental insurance giant Aflac (NYS: AFL) once again looks like it's delivered another knockout earnings report.
Aflac derives three-quarters of its revenue from Japan, so as you can imagine, following the tragic earthquakes in Japan in March, the company's bottom line suffered. As Japan's people recover from the disaster, so has Aflac -- and in a big way.
First, prospects in Europe are improving, which is an immediate boost to Aflac since it has a chunk of its investment portfolio tied to European debt. Today's negotiated debt deal, while not a white knight to the European debt debacle, is a step in the right direction to stabilizing the region's financial system. During the first half of 2011, Aflac was forced to realize $1 billion in losses tied to its European investments. With Europe's outlook beginning to brighten, Aflac's investment portfolio should receive a nice boost.
Even though Aflac's quarterly report was skewed by favorable currency translations from the yen into U.S dollars, the underlying figures behind its growth are unmistakably bullish. For such a large insurance company, a 22% jump in annualized premium sales in Japan can only be described as remarkable. Even its U.S sales have been strong with investment income jumping by 8.5% during the quarter.
But let's not beat around the bush here. The real reason investors should be jumping at the chance to own Aflac is because it puts shareholders first. Aflac announced its 29th consecutive annual dividend increase to $0.33 per share, payable to shareholders in the fourth quarter. This places Aflac, even after yesterday's near-10% pop, at a very tempting 2.8% yield.
Perhaps more impressive, Aflac continues to reinvest in its business and its shareholders' future. Aflac anticipates spending $300 million on share repurchases in 2011 and expects this number to double in 2012 to $600 million -- but wait, I'm not done. The company also projects this figure could yet again double to more than $1 billion in share buybacks in 2013. Twenty-nine years of increasing dividends and increasing share buybacks -- now that's confidence in your business.
The crazy thing is that even after yesterday's meteoric move higher, Aflac is still cheaply valued at just over 7 times forward earnings. It boasts better operating margins than rivals MetLife (NYS: MET) , and Sun Life Financial (NYS: SLF) , while offering a higher dividend yield than both Prudential Financial (NYS: PRU) and Primerica (NYS: PRI) .
My advice is that if this duck quacks, you listen!
What do you think the future holds for Aflac? Share your thoughts in the comments section below, and consideradding this dividend aristocratto your free and personalized watchlist to keep up on the latest news with the supplemental insurance giant.
At the time this article was published Fool contributorSean Williamshas no material interest in any companies mentioned in this article. He likes cash, which, he has been told, is just as good as money. You can follow him on CAPS under the screen nameTMFUltraLongand on Twitter, where he goes by the handle@TMFUltraLong. The Motley Fool owns shares of Aflac.Motley Fool newsletter serviceshave recommended buying shares of Aflac. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policythat pays its shareholders in transparency.